Sign In
Buy HOWL
$0.362
-0.0084 (-2.27%)
At Close: Jun 23, 2026
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
10:26am, Friday, 03'rd Nov 2023
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company tre
WATERTOWN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developme
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 05'th Sep 2023
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the developmen
Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets
04:48pm, Friday, 25'th Aug 2023
Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
10:01am, Thursday, 10'th Aug 2023
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago.
New Strong Buy Stocks for July 26th
08:40am, Wednesday, 26'th Jul 2023
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
07:00am, Thursday, 01'st Jun 2023
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
09:56am, Thursday, 11'th May 2023
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.56 per share a year ago.
Werewolf Therapeutics to Participate in May Investor Conferences
07:00am, Monday, 01'st May 2023
WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
09:54am, Thursday, 23'rd Mar 2023
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Tuesday, 07'th Feb 2023
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of W
4 Penny Stocks To Buy In January According To Insiders
02:14pm, Friday, 20'th Jan 2023
Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
New Strong Buy Stocks for January 20th
07:32am, Friday, 20'th Jan 2023
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
New Strong Buy Stocks for January 18th
09:47am, Wednesday, 18'th Jan 2023
DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Thursday, 10'th Nov 2022
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
